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19F-NMR Reveals the Role of Mobile Loops in Product and Inhibitor
Binding by the S¼o Paulo Metallo-b-Lactamase
Martine I. Abboud, Philip Hinchliffe, Jgrgen Brem, Robert Macsics, Inga Pfeffer, Anne Makena,
Klaus-Daniel Umland, Anna M. Rydzik, Guo-Bo Li, James Spencer, Timothy D. W. Claridge,*
and Christopher J. Schofield*
Abstract: Resistance to b-lactam antibiotics mediated by
metallo-b-lactamases (MBLs) is a growing problem. We
describe the use of protein-observe 19F-NMR (PrOF NMR)
to study the dynamics of the S¼o Paulo MBL (SPM-1) from b-
lactam-resistant Pseudomonas aeruginosa. Cysteinyl variants
on the a3 and L3 regions, which flank the di-ZnII active site,
were selectively 19F-labeled using 3-bromo-1,1,1-trifluoroace-
tone. The PrOF NMR results reveal roles for the mobile a3
and L3 regions in the binding of both inhibitors and hydro-
lyzed b-lactam products to SPM-1. These results have impli-
cations for the mechanisms and inhibition of MBLs by b-
lactams and non-b-lactams and illustrate the utility of
PrOF NMR for efficiently analyzing metal chelation, identify-
ing new binding modes, and studying protein binding from
a mixture of equilibrating isomers.
Hydrolysis catalyzed by b-lactamases is one of the most
important mechanisms of resistance to b-lactam antibiotics.[1]
Although b-lactamases employing a mechanism involving
a nucleophilic serine (classes A, C, and D) have well-
established roles in resistance to b-lactams, the class B ZnII-
dependent metallo-b-lactamases (MBLs) have more recently
emerged as a major clinical problem (Figure 1A).[2] Clinically
useful inhibitors of the class A b-lactamases (e.g., clavulanic
acid) are widely used, and avibactam has recently been
reported as a broad-spectrum serine b-lactamase inhibitor;[3]
however, no such inhibitors exist for the MBLs.[4]
The S¼o Paulo MBL-1 (SPM-1) was first identified in b-
lactam-resistant Pseudomonas aeruginosa,[5] and SPM-1-pro-
ducing P. aeruginosa is endemic in Brazilian hospitals.[6]
Recent reports of SPM-1-mediated resistance in Europe,
Asia, and North America reveal its global spread.[7] SPM-1 is
a particular challenge from an inhibition perspective because
it has a broad substrate specificity (catalyzing penicillin,
cephalosporin, and carbapenem hydrolysis) and has proper-
ties characteristic of both B1- and B2-subfamily MBLs
(Figure S1 in the Supporting Information).[8] SPM-1 resembles
B1 MBLs in terms of its di-ZnII ion requirement and (based
on available evidence) with respect to its kinetics.[9] SPM-
1 has unusual second-sphere residues,[10] and is unique
amongst B1 MBLs with respect to mobile active-site regions;
SPM-1 has an extended “a3 region” (residues 223–241, BBL
numbering) and a relatively short L3 loop (residues 61–66,
BBL numbering), which are features characteristic of B2
MBLs.[8a] No structures of SPM-1 complexed with substrates/
inhibitors have been solved, though structures in which the a3
Figure 1. A) Outline mechanism for metallo-b-lactamases (MBLs).
Views of SPM-1 structures in B) “open” (PDB ID: 2FHX)[8a] and
C) “closed” (PDB ID: 4BP0)[8b] conformations of the a3 region. (Y58
was refined in two conformations in the former).[8a] SPM-1 has
a characteristic elongated a3 region (green) and a short L3 loop
(orange). Sites of labeling by cysteine alkylation with 3-bromo-1,1,1-
trifluoroacteone are identified by residue numbers. Note that the
active cysteine (Cys221) is not labeled since it chelates ZnII.
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region adopts open[8a] and closed[8b] conformations with
respect to the active site have been reported (Figure 1B,C).
Owing to its intrinsic sensitivity, lack of resonance overlap,
and advances in NMR instruments and probe design, protein-
observe 19F-NMR (PrOF NMR) is of increasing utility in
studying conformational changes and protein–ligand inter-
actions.[11] We have reported on the use of PrOF NMR to
study MBL dynamics using cysteine alkylation by 3-bromo-
1,1,1-trifluoroacetone (BTFA) to efficiently introduce fluo-
rine labels (Figure S2A).[8b,12] Here, we describe PrOF NMR
studies on SPM-1 that inform on the relative importance of
the L3 loop and a3 region in the binding of different classes of
MBL substrates/inhibitors. Importantly, they reveal that the
hydrolyzed b-amino acid products of MBL catalysis can bind
to SPM-1 in a process involving the L3 loop.
Residues in the L3 loop (Y58) and a3 region (F151) were
selected for modification and labeling with 19F (Figure S2B).
In initial work, we had labeled Y152;[8b] however, we selected
F151 for further studies because analysis of SPM-1 crystal
structures[8] implies that the F151 sidechain is mobile and
projects closer to the active-site zinc ions than that of Tyr152
(Figure S3). Selective labeling of Y58C and F151C SPM-
1 variants using BTFA (Y58C* and F151C*, respectively) was
confirmed by intact-protein and trypsin-digest mass spec-
trometry (Figures S4–11). Notably, the naturally present
cysteine (Cys221) in SPM-1 was not observed to react with
BTFA, likely because it chelates ZnII, as evidenced by S-
carbamidomethylation of Cys221, but not Cys58 and Cys151,
in MS analyses of Y58C* and F151C* (Figures S8–11). The
circular dichroism spectra[13] of wildtype (wt) SPM-1, Y58C*,
and F151C* were similar (Figure S12), thus implying similar
overall folds as supported by crystallographic analyses of
Y58C (Figures S13,14 and Table S1). Kinetic analyses[14]
(Figure S15) implied that the introduction of the
CH2COCF3 label did not substantially alter the substrate
affinity, that is, similar KM values were obtained for merope-
nem with wt SPM-1 and both labeled variants. A 2.5-fold
decrease in kcat for meropenem with both SPM-1* variants
was observed, possibly reflecting interactions involving the
modified residue in enzyme–intermediate complexes. The
combined biophysical and kinetic studies established that the
properties of Y58C* and F151C* are sufficiently similar to
those of wt SPM-1 to justify PrOF NMR studies. Together
with earlier studies on protein alkylation by BTFA,[15] these
results demonstrate that BTFA is useful for the efficient
introduction of 19F labels through post-translational cysteine
alkylation.
The 19F-NMR spectra revealed major protein-observe
peaks at @83.15 ppm (Y58C*) and @84.75 ppm (F151C*;
Figure S16), thus indicating that the labeled loops/regions of
the variants exist predominantly in a single conformation or,
more likely, that the labeled residues are moving rapidly
relative to the NMR shift timescale. The F151C* variant also
displayed broad signals on either side of the sharper peak at
@84.75 ppm, possibly reflecting conformational motion; how-
ever, we did not observe changes in the line width and
intensity of the signal in variable-temperature studies (277 K
to 310 K). Consistent with the crystallographic evidence,
solvent isotope exchange studies (Figure S17) revealed that
F151C*, which lies in the exposed a3 region, is more solvent
accessible than Y58C*, which is located in the less exposed L3
loop.
We then used PrOF NMR (Figure S18) to investigate the
binding of representative MBL ligands to Y58C* and F151C*
SPM-1 (Table S2, see Table S3 for KD values). Initially, we
tested reported MBL inhibitors to validate use of the SPM-1*
variants for investigating ligand binding. With the zinc
chelator 1,10-o-phenanthroline, new NMR peaks were
observed for both Y58C* (Figure 2A)and F151C* (Fig-
ure 2B). These peaks are the same as those observed in the
apo-SPM-1* spectra, which is consistent with the anticipated
ZnII extraction in solution by 1,10-o-phenanthroline; 1,10-o-
phenanthroline itself was not observed to bind to apo-Y58C*
(Figure 2A and Figures S19,20). These results reveal the
utility of PrOF NMR in detecting metal chelation/binding in
solution and/or to the protein, which is not always readily
accessible through metallo-enzyme inhibition studies. With
rhodanine ML302 and thioenol ML302F,[16] new peaks at
@83.75 ppm and @84.40 ppm for Y58C* and F151C*, respec-
tively, were observed (Figure S21). These observations are
consistent with hydrolysis of ML302 to give the thioenol
ML302F under the incubation conditions.[17] l-Captopril,
which inhibits B1 MBLs but not SPM-1 (IC50 > 500 mm)
[18]
and subclass B2 MBLs,[19] did not manifest substantial
changes in the 19F spectrum for either of the SPM-1* variants
(Figure S22).
Isoquinolines are broad-spectrum MBL inhibitors,[13,14]
but their binding mode is unknown. Significant line broad-
ening, which is typical of a system in intermediate exchange,
Figure 2. PrOF NMR monitoring of inhibitor binding to SPM-1*. 19F-
NMR spectra of the interactions of 1,10-o-phenanthroline with
A) Y58C* SPM-1 and B) F151C* SPM-1. 19F-NMR spectra of the
interactions of 1 with C) Y58C* SPM-1 and D) F151C* SPM-1. Assay
mixtures: 40 mm SPM-1* in 50 mm Tris, pH 7.5, 9:1 H2O/D2O.
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was observed when isoquinoline (1)[13, 14] was titrated with
Y58C*. Addition ofML302F[17] to a sample containing Y58C*
and 1 led to the appearance of the peak characteristic of the
ML302F-bound complex and a new peak deshielded by
1.1 ppm relative to that of the Y58C* peak (Figure 2C). With
F151C*, 1 induced broadening and chemical-shift changes
(Figure 2D). Thus, binding of 1 influences both the a3 and L3
regions (Figures S22–24). Interestingly, however, the results
imply that 1 binds to SPM-1 in the presence ofML302F, which
is known to bind to the active site zinc ions.[17] Together with
the observation that 1 binds to apo-Y58C* as evidenced by
line broadening (Figure 2C), the results imply that 1 binds to
SPM-1 in an unprecedented manner that does not involve
coordination to the zinc ions.
We then tested the utility of PrOF NMR for monitoring
the binding of weak SPM-1 inhibitors, as exemplified by
avibactam, which inhibits class A, C, and some D b-lactama-
ses,[3,4c] but has low affinity for most MBLs.[4b] A clear
chemical-shift change was observed with avibactam and
Y58C* but not F151C*, thus indicating that avibactam
binding induces changes in the L3 region but not the a3
region (Figures S25,26). With Y58C*, a shift back to the
original protein peak was observed after 12 h, likely as a result
of slow hydrolysis of avibactam catalyzed by SPM-1.[4b]
Addition of fresh avibactam to the reacted solution shifted
the peak towards that arising originally from avibactam with
Y58C*.
We then investigated the addition of b-lactam substrates
[a carbapenem (meropenem), a penicillin (piperacillin), and
mechanism-based inhibitors of class A b-lactamases (tazo-
bactam and clavulanic acid)] to the SPM-1* variants. Their
addition to SPM-1* caused line broadening and chemical-
shift changes for Y58C* but not (within detection limits) for
F151C* (Figure 3).[8b] Meropenem treatment (400 mm) of
Y58C* (40 mm) led to a 0.2 ppm 19F shift (from @83.15 ppm
to @82.95 ppm), thus implying fast exchange (Figure 3A,E).
Time-course analysis revealed spectra that are stable for 12 h
(Figure 3C), thus suggesting that the new peak likely reflects
an enzyme–product complex (Figures S27–31). With pipera-
cillin (400 mm), a shift of 0.4 ppm was also observed (Fig-
ure 3B,F). However, in contrast to meropenem, time-course
analysis revealed additional line broadening and a further
chemical shift of 0.18 ppm relative to the product complex
peak from @82.75 ppm to @82.57 ppm (Figure 3D and Fig-
ure S32), thus indicating production of a new SPM-1 binding
species.
Previous work has revealed that the product of piper-
acillin hydrolysis can bind to penicillin-binding proteins, with
the “epimerized” (5S)-product binding in preference to the
initially formed (5R)-penicilloic acid (PA).[20] We thus used
1H NMR to evaluate the time-dependent SPM-1-catalyzed
hydrolysis of piperacillin (Figure S33). The results reveal that
SPM-1 catalyzes piperacillin hydrolysis to give (5R)-PA,
which epimerizes relatively slowly to give (5S)-PA, likely
through a non-enzyme-catalyzed pathway. To investigate
binding of (5S)-PA and (5R)-PA to SPM-1, the Bacillus
cereusBcII MBL[14]was used to produce PA from piperacillin,
which was then purified. Addition of the resultant (5S)/(5R)-
PA mixture to Y58C* led to a peak at @82.57 ppm, as
observed after 12 h in the piperacillin time course (Figure 4).
1H and water LOGSYanalyses revealed binding of both (5S)-
PA and (5R)-PA to SPM-1 (Figure S34).
We then used PrOF NMR to investigate interactions of
SPM-1 with the class A SBL inhibitors clavulanic acid and
Figure 3. Interactions of (hydrolyzed) b-lactams with SPM-1* variants
as analyzed by by PrOF NMR. Titration of A) meropenem and
B) piperacillin with Y58C* SPM-1 reveals interactions with the L3
region. Time-course analyses (after 12 h) of C) meropenem and
D) piperacillin with Y58C* SPM-1 are consistent with a stable protein–
product peak with an additional shift in the case of piperacillin, which
indicates the formation of a new species. Titration of E) meropenem
and F) piperacillin into a solution of F151C* SPM-1 shows no
substantial changes. Assay mixtures: 40 mm SPM-1* and increasing
ligand concentrations (up to 400 mm) in 50 mm Tris, pH 7.5, 9:1 H2O/
D2O. For Ddmax<0.1 ppm, observations are denoted as “no substantial
changes”.
Figure 4. 19F-NMR spectra of Y58C* SPM-1 interacting with hydrolyzed
piperacillin. The structures of piperacillin and its hydrolyzed products
[(5R)-PA and (5S)-PA] are shown. Assay mixtures: 40 mm Y58C* SPM-
1 and 400 mm added ligand in 50 mm Tris, pH 7.5, 9:1 H2O/D2O.
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tazobactam, which are SPM-1 substrates.[8a] Line broadening
and a shift from @83.15 to @83.02 and @82.98 ppm were
observed in the 19F Y58C* spectra for tazobactam and
clavulanic acid, respectively; no further substantial changes
were evident after 12 h. No such effects were observed for
F151C* (Figures S35–39). The propensity of clavulanic acid
and tazobactam to undergo complex fragmentations[21] (as
observed with SBLs) precluded identification of the species
that give rise to these shifts. In the case of clavulanic acid,
1H NMR studies (Figure S40) indicated the formation of
multiple products, only some of which likely bind to SPM-1.
The overall results reveal the importance of the dynamic
a3 and L3 regions in ligand binding by SPM-1. They also
illustrate how PrOF NMR can reveal previously unidentified
binding modes, as observed with isoquinoline (1). All of the
inhibitors tested, including the ZnII chelator 1,10-o-phenan-
throline, bring about substantial changes in both the a3 and
L3 regions, thus emphasizing the importance of both,
particularly the a3 region, in inhibitor development. In
contrast, the b-lactam substrates (piperacillin, meropenem,
tazobactam, and clavulanate) give rise to hydrolyzed products
which bring about changes in the L3 region. Although it is
possible that substrate binding involves both the a3 and L3
regions, the latter is more important in product binding, and
hence likely in product release too. This is consistent with the
proposal indicating that SPM-1 is mechanistically closer to the
B1 rather than B2 MBLs,[8b] based on work showing that
deletion of the SPM-1 a3–a4 region does not substantially
affect b-lactam hydrolysis,[8a] and crystallographic studies on
the B1 MBL NDM-1 implying that binding of hydrolyzed
meropenem involves the L3 region (Figure S31).[22] With the
penicillin substrates, we observed binding of both (5R)-PA
and (5S)-PA, thus illustrating the utility of PrOF NMR for
studying the binding of equilibrating mixtures of stereoiso-
mers. The observation of penicilloic acid and hydrolyzed
meropenem binding to SPM-1 is of potential clinical rele-
vance. Previous studies have shown that penicilloic acids are
competitive inhibitors of serine b-lactamases[23] and MBLs.[24]
Although the levels of inhibition by penicilloic acids are much
less than those for the intact b-lactams, given the high
concentration of b-lactams used clinically, it is possible that b-
lactamase inhibition by PAs is relevant. The results are of
interest for identifying novel inhibitor scaffolds for SPM-
1 and other MBLs, including the design of non-b-lactam
inhibitors that are not susceptible to b-lactamase hydrolysis,
and/or b-lactams or b-lactam analogues that give hydrolyzed
products that inhibit MBLs. Whist 13C/15N labeling is often
powerful for studying ligand binding, it is relatively expensive
and time consuming. In contrast, our results clearly illustrate
the utility of PrOF NMR for studying protein–ligand inter-
actions in solution, detecting metal chelation, and revealing
subtle differences in binding modes.
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